Accomplishments

SMS Pharmaceuticals Limited Accomplishments

2022

Successfully completed US FDA Remote Regulatory Assessment at our Analytical Testing Facility (CLAS)

2021

Successfully commercialized Remdesivir & Favipiravir which were authorized in emergency treatment of Covid-19.

2021

Dedicated Ibupforen manufacturing block inaugurated.

2020

Successfully completed EU GMP inspection by EDQM at our Bachupally facility.

2020

Successfully completed 3rd US FDA inspection at our Vijayanagaram facility.

2020

Successfully completed 1st US FDA inspection at our Analytical Testing Facility (CLAS)

2019

Central Laboratory Analytical Services (CLAS) established to cater analytical services using hyphenated analytical techniques.

2017

Demerged SMS group into 2 Entities – SMS Pharmaceuticals, SMS Lifesciences.

2017

Successfully completed PMDA- Japan inspection at our Bachupally facility.

2017

Successfully completed 5th US FDA inspection at our Bachupally facility.

2015

Successfully completed 2nd US FDA inspection at our Vijayanagaram facility.

2015

Won the prestigious “Indian Pharma Bulk drug company of the year” award and “Best bulk drug export company of the year” award from Govt. of India.

2014

Renewal of EU-GMP certification by Hamburg Health Authority (BGV) is successful at our Bachupally facility.

2014

Successfully completed 4th US FDA inspection at our Bachupally facility.

2012

Commercial production started in our world class API facility, Vijayanagaram.

2012

Successfully completed 1st US FDA inspection at our Vijayanagaram facility.

2011

Successfully completed 3rd US FDA inspection at our Bachupally facility.

2011

EU-GMP certification by Hamburg Health Authority (BGV) is successful at our Bachupally facility.

2010

Started a green field project to build an API facility in more than 100 acres of Land.

2009

DSIR recognized our Gagillapur R&D center.

2008

Successfully completed 2nd US FDA inspection at our Bachupally facility.

2008

Inauguration of state of the art R&D Center at Gagillapur, Hyderabad.

2007

SMS got listed on the NSE, BSE (Indian stock exchange) – Public Listed company.

2005

DSIR recognized our in-house R&D center.

2004

In-house R&D center established at Sanath Nagar, Hyderabad.

2003

Faced our first USFDA audit (successfully); SMS API was Part of a Para IV filing from an MCN company.

2001

Successfully commercialized Sumatriptan Succinate at our Bachupally facility.

1997

Recognized by govt. of India with a Jawaharlal Silver rolling trophy for the best productivity of the year.

1995

Became the Largest manufacturer of Ranitidine API in the world.

1989

SMS Pharma was started with single Unit, single product facility.

  • 2022

Successfully completed US FDA Remote Regulatory Assessment at our Analytical Testing Facility (CLAS)

  • 2021

Successfully commercialized Remdesivir & Favipiravir which were authorized in emergency treatment of Covid-19.

  • 2021

Dedicated Ibupforen manufacturing block inaugurated.

  • 2020

Successfully completed EU GMP inspection by EDQM at our Bachupally facility.

  • 2020

Successfully completed 3rd US FDA inspection at our Vijayanagaram facility.

  • 2020

Successfully completed 1st US FDA inspection at our Analytical Testing Facility (CLAS)

  • 2019

Central Laboratory Analytical Services (CLAS) established to cater analytical services using hyphenated analytical techniques.

  • 2017

Demerged SMS group into 2 Entities – SMS Pharmaceuticals, SMS Lifesciences.

  • 2017

Successfully completed PMDA- Japan inspection at our Bachupally facility.

  • 2017

Successfully completed 5th US FDA inspection at our Bachupally facility.

  • 2015

Successfully completed 2nd US FDA inspection at our Vijayanagaram facility.

  • 2015

Won the prestigious “Indian Pharma Bulk drug company of the year” award and “Best bulk drug export company of the year” award from Govt. of India

  • 2014

Renewal of EU-GMP certification by Hamburg Health Authority (BGV) is successful at our Bachupally facility.

  • 2014

Successfully completed 4th US FDA inspection at our Bachupally facility.

  • 2012

Commercial production started in our world class API facility, Vijayanagaram.

  • 2012

Successfully completed 1st US FDA inspection at our Vijayanagaram facility.

  • 2011

Successfully completed 3rd US FDA inspection at our Bachupally facility.

  • 2011

EU-GMP certification by Hamburg Health Authority (BGV) is successful at our Bachupally facility.

  • 2010

Started a green field project to build an API facility in more than 100 acres of Land.

  • 2009

DSIR recognized our Gagillapur R&D center.

  • 2008

Successfully completed 2nd US FDA inspection at our Bachupally facility.

  • 2008

Inauguration of state of the art R&D Center at Gagillapur, Hyderabad.

  • 2007

SMS got listed on the NSE, BSE (Indian stock exchange) – Public Listed company.

  • 2005

DSIR recognized our in-house R&D center.

  • 2004

In-house R&D center established at Sanath Nagar, Hyderabad.

  • 2003

Faced our first USFDA audit (successfully); SMS API was Part of a Para IV filing from an MCN company.

  • 2001

Successfully commercialized Sumatriptan Succinate at our Bachupally facility.

  • 1997

Recognized by govt. of India with a Jawaharlal Silver rolling trophy for the best productivity of the year.

  • 1995

Became the Largest manufacturer of Ranitidine API in the world.

  • 1989

SMS Pharma was started with single Unit, single product facility.

SMS Pharmaceuticals Limited Accomplishments

SMS Pharmaceuticals Ltd is one of the leading pharmaceutical manufacturing companies in India with world-class facilities, with a wide range of process equipment fully compliant with the cGMP and WHO Standards

INVESTORS DESK